MegatrendsMegatrends: not the usual suspects, but who actually profits.View megatrends →

Metrics as of 10/15/2026, 11:40 PM (Berlin time), refresh in progress.

Cardiol Therapeutics Stock

Cardiol Therapeutics Inc.

CRDLNASDAQMarkt
US$1.15
+0.9% today

Company data

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
Canada
CEO
David G. Elsley
Employees
18
Market cap
$139 M
IPO
15/01/2019

Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III…

Cardiol Therapeutics stock: price history

15/10/25+6.5 %15/10/26

1D

+0.9%

1W

-11.5%

1M

-37.8%

6M

-18.4%

YTD

+20.6%

1Y

+6.5%

2Y

-39.8%

5Y

-70.7%

10Y

–

Next earnings date

Next earnings date

12/11/2026 (in 26 days)

Volatility around earnings

~9% stronger price swings than usual

Ask the agents about Cardiol Therapeutics

Analyst assessment of Cardiol Therapeutics

PRICE TARGET LOW

US$8.00

CONSENSUS

US$8.00

MEDIAN

US$8.00

PRICE TARGET HIGH

US$8.00

0

STRONG BUY

2

BUY

0

HOLD

0

SELL

0

STRONG SELL

2

TOTAL · Buy

As of: 23/09/2026

ANALYST FIRMRATINGACTIONDATE
HC Wainwright & Co.Buymaintain23/09/2026
Canaccord GenuityBuymaintain17/08/2026
HC Wainwright & Co.Buymaintain14/07/2026
Canaccord GenuityBuymaintain06/04/2026
HC Wainwright & Co.Buymaintain10/02/2026
HC Wainwright & Co.Buymaintain01/12/2025
HC Wainwright & Co.Buymaintain16/04/2025 (older than 12 months)
HC Wainwright & Co.Buymaintain07/04/2025 (older than 12 months)

Cardiol Therapeutics stock metrics

P/E

-4.65

P/B

7.65

EV/EBITDA

-4.7

RETURN ON EQUITY

-36.0%

NET MARGIN

0.0%

DEBT/EQUITY

0

DIVIDEND YIELD

0.0%

AS OF

30/06/2026

Free float & liquidity

FREE FLOAT

76.2%

FLOAT SHARES

91,975,657

AVG. DAILY VOLUME (30D)

1,535,702

Institutional holders

FUND / INSTITUTIONSHARESCHANGEAS OF
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC0-22,34030/09/2026
MMCAP International Inc. SPC15,598,560+246,24330/06/2026
Tejara Capital Ltd5,113,822-16,30030/06/2026
Ikarian Capital, LLC3,325,000+600,00030/06/2026
BOOTHBAY FUND MANAGEMENT, LLC975,721+180,84030/06/2026
Page 1 / 3

Comparable stocks

Frequently asked questions about Cardiol Therapeutics stock

What does Cardiol Therapeutics do?

Cardiol Therapeutics Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in Canada.

The CEO is David G. Elsley, the company employs around 18 people.

The IPO was on 15/01/2019; the stock trades on NASDAQ under the ticker CRDL.

What do analysts say about Cardiol Therapeutics stock?

2 analysts rate the stock, the consensus is Buy (as of 23/09/2026).

The average price target is US$8.00, ranging from US$8.00 to US$8.00, with a median of US$8.00.

This is an external assessment, not a statement by Market Jury.

When does Cardiol Therapeutics report next?

The next earnings date is 12/11/2026.

Around past earnings, price swings were roughly 9% stronger than usual.

Does Cardiol Therapeutics pay a dividend?

No, Cardiol Therapeutics currently does not pay a dividend.

Which stocks are comparable to Cardiol Therapeutics?

Comparable stocks include Merck, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Zoetis, Sandoz Group, Viatris, Lantheus Holdings and Amneal Pharmaceuticals.

How can I get Cardiol Therapeutics stock analyzed?

Clicking "Analyze stock" lets five strategies assess Cardiol Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.

Not investment advice. Past performance is not an indicator of future results.